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PEOPLE with flulike symptoms who seek treatment at a medical clinic or 
hospital often must wait several hours 
before being examined, possibly exposing 
many people to an infectious virus. If 
a patient appears to need more than the 
routine fluids-and-rest prescription, 
effective diagnosis requires tests that must 
be sent to a laboratory. Hours or days may 
pass before results are available to the 
doctor, who in the meantime must make an 
educated guess about the patient’s illness. 
The lengthy diagnostic process places a 
heavy burden on medical laboratories and 
can result in improper use of antibiotics or 
a costly hospital stay.
A faster testing method may soon be 
available. An assay developed by a team 
of Livermore scientists can diagnose 
influenza and other respiratory viruses 
in about two hours once a sample has 
been taken. Unlike other systems that 
operate this quickly, the new device, called 
FluIDx (and pronounced “fluidics”), can 
differentiate five types of respiratory 
viruses, including influenza. FluIDx can 
analyze samples at the point of patient 
care—in hospital emergency departments 
and clinics—allowing medical providers 
to quickly determine how best to treat 
a patient, saving time and potentially 
thousands of dollars per patient.
The FluIDx project, which is led by 
Livermore chemist Mary McBride of 
the Physics and Advanced Technologies 
Directorate, received funding from the 
National Institute of Allergy and Infectious 
Diseases and the Laboratory Directed 
Research and Development (LDRD) 
Program. To test the system and make it as 
useful as possible, the team worked closely 
with the Emergency Department staff at 
the University of California (UC) at Davis 
Medical Center in Sacramento. Robert 
Derlet, M.D. and chief of the department, 
is enthusiastic about having FluIDx 
available for testing. 
“A dozen or more viruses cause 
symptoms in people that all look the same 
in the early stages,” says Derlet. “With 
most viruses, people are sick for just a few 
days and then get better. But flu and other 
A new Livermore tool can quickly tell 
In the background, a micrograph shows the morphologic features found in the 1918 influenza virus. 
(Photographer: Cynthia Goldsmith. Reprinted courtesy of the Centers for Disease Control and 
Prevention.)
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respiratory viruses can make some people 
really sick and even kill them. We need to 
be able to sort out the ‘bad guys’ so these 
viruses don’t infect others.” 
From the Lab to the Clinic
Flu kills more than 35,000 people every 
year in the U.S. (See the box on p. 5.) The 
2003 outbreak of severe acute respiratory 
syndrome and the ongoing concern about 
a possible bird flu pandemic illustrate 
the need for a fast, reliable test that 
can differentiate seasonal flu from a 
potentially pandemic influenza. Such a 
test should also discriminate influenza 
from pathogens that cause illnesses with 
flulike symptoms. 
FluIDx team members 
(from left) Jim Birch, 
Jack Regan, and 
Kristl Adams view 
results from a recent 
test. The system can 
diagnose influenza 
and other respiratory 
viruses in about two 
hours after a sample 
is taken.
When a precise diagnosis is required 
to treat an adult patient with serious 
respiratory symptoms, sample cells are 
usually obtained with a nasal or throat 
swab and analyzed with one of several 
laboratory methods. The gold standard 
test is viral culturing, a highly sensitive 
method that can identify the specific 
strain of virus. However, viral culturing 
is a labor-intensive process and requires 3 
to 10 days to produce results, far too long 
for early intervention. Enzyme and optical 
immunoassays offer results in 30 minutes, 
but these methods are less sensitive than 
viral culturing so they can produce false 
positives or negatives. They also cannot 
distinguish the type of virus found.
Direct immunofluorescence antibody 
(DFA) staining is as sensitive as viral 
culturing. It also can detect multiple 
respiratory pathogens simultaneously 
by a process known as multiplexing. 
However, DFA staining requires expensive 
equipment, a skilled microscopist, 
and samples with enough target cells 
for testing. In addition, the results are 
ultimately subjective. Another method, 
called reverse transcriptase-polymerase 
chain reaction assay, offers sensitivity and 
specificity comparable to viral culturing 
and DFA staining. It also produces results 
in two hours and can rapidly test a large 
number of samples. The drawback with 
these tests, however, is that they must be 
performed in a laboratory. None of them 
can be used where they are needed most: in 
the clinic or emergency department where 
patients are being treated.
which patients have influenza or another respiratory virus.
FluIDx
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Livermore’s FluIDx diagnostic system, 
with its instrumentation and multiplexed 
assays, is designed specifically for point-
of-care diagnosis. The fast, easy-to-use 
system is based on the Autonomous 
Pathogen Detection System, a homeland 
security technology developed by 
Lawrence Livermore. This R&D 100 
Award–winning technology constantly 
monitors the air to detect airborne 
bioterrorism agents, such as anthrax.  
(See S&TR, October 2004, pp. 4–5.)
FluIDx is an integrated system designed 
to perform highly multiplexed polymerase 
chain reaction (PCR) nucleic-acid-based 
assays in real time. The FluIDx system 
processes a sample, analyzes the data, 
reports the results, and decontaminates 
itself before another sample is taken. The 
device currently uses 16 assays—12 for 
individual nucleic-acid targets and 4 for 
internal controls. The assays can 
simultaneously detect influenza A and B, 
parainfluenza (Types 1 and 3), respiratory 
syncytial virus, and adenovirus (Groups B, 
C, and E).
Process for Assay Development
FluIDx works so well because its 
nucleic-acid-based detection assays have 
been carefully vetted using a proven 
assay-development process. As a result, 
the assays produced are extraordinarily 
sensitive, specific, and robust. 
The process begins with an analysis 
of all available genomic sequence 
information, which forms the basis for 
developing a signature—the region or set of 
regions on a chromosome that is unique to 
the target organism. Traditional approaches 
to developing DNA signatures start by 
identifying a gene that is considered vital to 
the target organism’s virulence, host range, 
or other distinctive factor. 
Livermore’s bioinformatics team has 
developed a whole-genome comparative 
analysis software system called KPATH 
to improve the signature-mining process. 
(See S&TR, April 2004, pp. 4–9.) KPATH 
aligns multiple genomes of different strains 
of the target species and compares them 
to identify all the genomes that contain 
the target sequence. These genomes are 
then compared with Livermore's immense 
database of microbial organisms to 
establish that the organism-conserved target 
sequence does not occur in other sequenced 
microbial organisms. An algorithm subtracts 
any target sequence already listed in the 
microbial organism database. The resulting 
sequence is mined for potential signature 
candidates. Additional electronic screening 
catches nonexact matches that might 
produce false positives.
The signature-mining process then 
moves from the computer to the laboratory 
to further reduce the field of candidates. 
Potential nucleic-acid signatures are 
screened against more than 2,500 randomly 
selected nucleic-acid extracts from soils, 
microbes, bacteria, and other organisms 
that may be present in a sample when it 
is collected. Candidate signatures are also 
exposed to near-neighbor nucleic acids to 
reduce the potential for false results.
 Signatures that pass the intensive 
background screening in real-time PCR 
are developed into assays in a format 
FluIDx team member 
Sonia Letant works on 
assay development.
(a) The FluIDx system uses a liquid array of 100 beads, each with a unique spectral value. (b) Nucleic-
acid probes capture beads that complement the target pathogens: influenza, respiratory syncytial 
virus (RSV), adenovirus, and severe acute respiratory syndrome (SARS). (c) Amplified nucleic acid is 
hybridized to fluorescently labeled beads and analyzed.
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What Is Flu?
Seasonal influenza, or the flu, is a contagious respiratory illness caused by viruses that 
spread in droplets from coughing and sneezing. Most adults may be able to infect others 
beginning one day before symptoms develop and up to five days after they become sick. 
Symptoms can include fever, headache, fatigue, cough, sore throat, runny nose, or muscle 
ache. Flu may cause only mild illness but also may lead to severe illness or even death. 
Although seasonal flu is often thought of as a trivial illness, statistics tell a different 
story. Every year in the U.S., 5 to 20 percent of the population typically gets the flu. More 
than 200,000 people are hospitalized from flu complications, and about 36,000 people 
die from flu. Fortunately, most people have some immunity to seasonal influenza, and a 
vaccine is developed annually. 
Common flu is usually caused by an influenza A virus. Avian, or bird, flu is a subtype 
of the influenza A virus that occurs naturally among birds. Different subtypes are caused 
by changes in certain proteins, such as hemagglutinin (HA) and neuraminidase (NA), on 
the surface of the influenza A virus and by the way the proteins combine. Some subtypes 
cause only mild symptoms. The bird flu subtype A/H5N1 is highly pathogenic, spreading 
rapidly among flocks of poultry. Its mortality rate can reach 90 to 100 percent, often within 
48 hours. 
Among humans, only three known influenza A subtypes are in circulation: A/H1N1, 
A/H1N2, and A/H3N2. The A/H5N1 bird flu variant is the most deadly of the few avian 
viruses to have crossed the species barrier to infect humans. Humans have no immunity 
to A/H5N1, and no vaccine is currently available. Since 2003, human A/H5N1 cases have 
been reported in Azerbaijan, Cambodia, China, Dijbouti, Egypt, Indonesia, Iraq, Thailand, 
Turkey, and Vietnam. More than half of the people infected with the A/H5N1 virus have 
died. To date, no human-to-human transmission of the disease has been sustained, but 
influenza viruses mutate rapidly. Health officials are concerned that A/H5N1 will evolve 
into a virus that can be transmitted from person to person.
Confusingly for physicians, other influenzalike illnesses start out looking almost exactly 
the same as common flu. Adenoviruses can affect not only the respiratory system but 
also the eyes, intestines, and urinary tract, most commonly in children. Parainfluenza and 
respiratory syncytial virus are common causes of lower respiratory tract disease in young 
children, and both can cause repeated infections throughout life. A tool such as FluIDx will 
help physicians quickly determine the cause of a patient’s flulike symptoms.
known as Taqman. At this stage, every 
parameter that might affect an assay’s 
performance is optimized, and all 
assays are fully characterized against a 
standardized panel of targets and near-
neighbors. The final results are captured 
in a certificate of analysis, providing a 
record of the assay’s pedigree.
 For the multiplexed liquid array format, 
individual signatures are added to the 
multiplexed PCR mix, with other panel 
signatures present. Signatures are tested 
several times to determine an assay’s 
detection limit for each target and to 
control for reactivity among signatures.
FluIDx at Work
The multiplexed nucleic-acid assays in 
FluIDx use tiny polystyrene microbeads 
colored with unique ratios of red- and 
orange-emitting dyes. The result is an array 
of 100 beads that can be distinguished 
by their spectral values. The beads are 
coated with nucleic-acid probes whose 
sequences complement those of the five 
target pathogens. Flow-through PCR 
amplifies nucleic acids from the viruses, 
and the amplified DNA, or amplicons, are 
introduced to the beads. The amplicons 
hybridize to their complementary probes 
on the appropriate bead. Then the beads 
are illuminated with red laser light, which 
has a wavelength of 635 nanometers, to 
classify each bead. Next, illumination with 
532-nanometer (green) laser light quantifies 
the assay at the bead’s surface based on the 
strength of the fluorescence. Conducting 
the multiplexed assay requires several steps 
and significant PCR thermocycling times, 
resulting in the two-hour duration for a 
FluIDx test.
Four control beads in every sample 
convey information about the system’s 
status. For example, the instrument 
control bead verifies the optics of the 
green laser. This bead is coated with a 
probe that is unlikely to bind to other 
nucleic acids and with a dye that emits 
a constant fluorescence in all samples. 
A change in fluorescence on the control 
bead indicates a fluctuation in the green 
laser’s performance. FluIDx analyzes every 
sample in the context of all four controls, 
thereby minimizing the likelihood of 
instrument malfunction or false results.
Livermore was not the first institution 
to use coated microbeads as indicators. 
However, says McBride, “We have put 
them to excellent use, applying them in 
several biosensors.” In the FluIDx system, 
the beads’ fluorescence signal above or 
below a threshold value indicates whether 
the assay is ruled positive or negative. 
The FluIDx sample preparation 
module and its detector are composed 
of commercially available parts with 
customized interfaces. The automated 
flow-through PCR unit, which was 
designed at Livermore, consists of a 
custom thermocycler with a copper 
heater mounted in line with the sample 
preparation unit. (See the figure on p. 6.) 
The software used in FluIDx is similar 
to that developed for the Autonomous 
Pathogen Detection System, but its 
user-interface has been designed so that 
personnel can operate the system with 
minimal training. This version is easy 
to use, readily accommodates hardware 
changes, and enables communication with 
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outside entities via an Ethernet connection 
or other medium.
Put to the Test 
In tests of FluIDx, a technician at 
the UC Davis Medical Center collected 
more than 1,200 nasal swab samples 
from patients seeking treatment in the 
Emergency Department. As part of 
the federal requirements for research 
involving human subjects, study 
participants signed informed consent 
forms before samples were taken, and 
the testing protocol was approved by 
UC Davis physicians and the governing 
Institutional Review Board. 
Nasal swabs were also collected from 
volunteers who showed no signs of illness. 
All samples were processed using viral 
culturing, DFA staining, and FluIDx. 
Sample comparisons revealed excellent 
results for FluIDx. In terms of sensitivity, 
the FluIDx multiplexed assays were on par 
with the results from viral culturing. The 
system’s specificity for identifying virus 
strains was significantly better than that 
obtained with DFA staining, which takes 
about the same time as FluIDx. 
The Work Goes On
The Laboratory works closely with the 
Centers for Disease Control and Prevention 
(CDC), which provided a few assays for 
the FluIDx panel. Livermore is part of 
the CDC Laboratory Response Network 
that would be activated in the event of a 
widespread flu pandemic. If the FluIDx 
system can be made small enough to be 
taken into the field, it could be used by 
emergency responders. A field-portable 
unit would be invaluable if a flu pandemic 
were to occur.
McBride and her team are developing 
additional assays that could be used to 
detect avian influenza (bird flu). Although 
the current panel can detect influenza A and 
B, it cannot differentiate normal seasonal 
flu from a potentially pandemic influenza. 
Influenza A is divided into subtypes based 
on the properties of two surface antigens, 
hemagglutinin (HA) and neuraminidase 
(NA). The HA antigen has 15 subtypes, and 
the NA has 9. Bird flu is subtype H5N1, 
while seasonal influenza is usually subtypes 
H1, H2, or H3.  
The team used KPATH to identify and 
select most of the candidate signatures 
included in the FluIDx respiratory panel. 
But KPATH could not identify nucleic-acid 
signatures in the required format for the 
HA gene, which is the basis for identifying 
the H subtypes of influenza A. Assays 
developed to operate in the Taqman PCR 
Copper
heater
Linear thermistor
Sample tube
Surface mount
resistors/heaters
Livermore’s automated flow-through polymerase chain reaction thermocycler includes a circuit-board 
heater and a copper heater.
The FluIDx device was tested in the Emergency 
Department of the University of California at 
Davis Medical Center. (a) Robert Derlet (right), 
M.D. and department chief, inserts a nasal swab 
sample collected from a volunteer into a vial and 
(b) places the vial in the FluIDx device. (c) Less 
than two hours later, a screen read-out provides 
test results.
(c)
(b)
(a)
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format handle one signature at a time. The 
HA gene, however, is highly divergent, so 
no single Taqman signature can capture all 
members of a subtype. 
To identify the smallest number of 
signatures required to recognize all 
members of a target set, the team used 
the Livermore software Minimal Set 
Clustering. This software generates sets 
of Taqman signatures that it predicts can 
be used in combination to detect all of the 
genome target sequences. Both KPATH 
and Minimal Set Clustering ensure that the 
signatures are predicted not to cross-react 
with a sequenced nontarget organism.
In designing signatures for the 
influenza A subtype called H5, McBride’s 
team obtained a target set of 217 H5 
sequences from Genbank, which is part 
of the National Center for Biotechnology 
Information. Minimal Set Clustering 
showed that four Taqman signatures 
are needed to detect all members of 
this target set. The H5 subgroups also 
appear to cluster by lineage, indicating 
that the signatures may discriminate 
where a strain originated. The first and 
fourth signatures detect groups of North 
American sequences, and the second and 
third detect Eurasian sequences. This 
distinction is critical because, to date, 
all avian flu strains infecting humans 
have been of Eurasian lineage. Similar 
work revealed the minimal number of 
signatures needed to provide complete 
coverage for the other influenza A 
subtypes, H1, H2, H3, and H7.
 McBride and her team are also 
working with the CDC’s Bioterrorism 
Rapid Response and Advanced 
Technology Laboratory, which will have 
lead responsibility for analyzing samples 
during a bioterror attack. Although 
the FluIDx instrument is designed for 
use in hospitals and medical clinics, 
the technology can be adapted for any 
situation in which rapid biological assays 
are needed. 
In October, the team submitted the 
FluIDx system to the U.S. Food and Drug 
Administration to have it approved as 
a medical device. “Approval will likely 
take about a year,” notes McBride. 
The Laboratory is already meeting 
with potential industrial partners who 
are interested in licensing the FluIDx 
technology for commercial use. 
In the meantime, the team continues 
to improve the assays and is working 
to automate a stand-alone device. The 
LDRD Program is supporting assay 
development to expand the FluIDx 
panel. Device testing will continue at 
the Emergency Department of the UC 
Davis Medical Center until June 2007. If 
additional funding is awarded, the team 
will build several next-generation systems 
with 10 separate (parallel) PCR reaction 
chambers to enable asynchronous sample 
processing. Asynchronous processing 
will, in turn, allow sample throughput that 
is better aligned with the requirements 
of busy hospitals, especially during the 
influenza season or in the event of a 
pandemic influenza.
The flu season arrives every year 
without fail, bringing fever, coughing, and 
runny noses. Soon perhaps, FluIDx will be 
a workhorse application, helping doctors 
decide how best to care for their patients.
—Katie Walter
Key Words: Autonomous Pathogen Detection 
System, FluIDx, influenza, KPATH, multiplex 
assays, point-of-care diagnosis, polymerase 
chain reaction (PCR), respiratory disease. 
For further information contact James Birch 
(925) 422-7105 (birch1@llnl.gov).
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Minimal Set Clustering software identifies the fewest number of signatures required to detect all 
members of a divergent target set. The branches on this phylogenetic tree show the four signatures 
needed to diagnose the relevant HA sequences of influenza A. The top two signatures target Eurasian 
strains, and the bottom two target North American strains.
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